← Back to Search
Intranasal Vaccines: Forthcoming Challenges.
Published 2000 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The mucosal epithelium of the upper respiratory tract constitutes an effective physical barrier to many pathogens. Its mucosal-associated lymphoid tissue is of particular importance for the protection and integrity of mucosal surfaces and the body's interior. Understanding the factors that influence the induction and regulation of mucosal immune responses will facilitate the design of vaccines capable of eliciting the appropriate type of protective immune response.
This paper references
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.
D. Klinman (1996)
Immune Response to Nasal Delivery of Antigenically Intact Tetanus Toxoid Associated with Poly(l‐lactic acid) Microspheres in Rats, Rabbits and Guinea‐pigs
A. Almeida (1993)
Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
L. Ågren (1997)
11 – Recombinant Adenoviruses as Vectors for Mucosal Immunity
K. Rosenthal (1996)
Antisense oligonucleotides: towards clinical trials.
S. Agrawal (1996)
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
B. Morein (1984)
Nasal Lymphoid Tissue (NALT) as a Mucosal Immune Inductive Site
H. Wu (1997)
Mucosal and systemic immune responses to measles virus haemagglutinin in mice immunized with a recombinant vaccinia virus.
N. Etchart (1996)
A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit
M. Pizza (1994)
Host responses to respiratory virus infection and immunization.
J. Crowe (1999)
Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.
W. S. Gallichan (1993)
12 – Poly(lactide-co-glycolide) Microencapsulation of Vaccines for Mucosal Immunization
J. Duncan (1996)
Cationic microparticles: A potent delivery system for DNA vaccines.
M. Singh (2000)
Biodegradable microspheres as a vaccine delivery system.
J. Eldridge (1991)
Induction of measles virus‐specific cytotoxic T‐cell responses after intranasal immunization with synthetic peptides
C. Partidos (1996)
The Waldeyer ring equivalent in the rat. A model for analysis of oronasopharyngeal immune responses.
P. Koornstra (1991)
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
M. McCluskie (1998)
The adjuvant effect of Vibrio cholerae and Escherichia coli heat‐labile enterotoxins is linked to their ADP‐ribosyltransferase activity
N. Lycke (1992)
Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
G. Hoyne (1993)
Intranasal immunization with liposomes induces strong mucosal immune responses in mice
J. Vadolas (1995)
The adjuvant effect of a non‐toxic mutant of heat‐labile enterotoxin of Escherichia coli for the induction of measles virus‐specific CTL responses after intranasal co‐immunization with a synthetic peptide
C. Partidos (1996)
In vivo responses to inhaled proteins. I. Quantitative analysis of antigen uptake, fate, and immunogenicity in a rabbit model system.
J. B. Willoughby (1977)
Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.
D. I. Jones (1997)
Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function.
J. Bennink (1990)
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
M. Yamamoto (1998)
CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines
A. Oxenius (1999)
Advances in vaccine adjuvants
M. Singh (1999)
Immunological adjuvants: a role for liposomes.
G. Gregoriadis (1990)
Fibronectin‐binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route
E. Medina (1998)
Vaccines. New approaches to immunological problems.
R. Ellis (1992)
Activation of human B cells by phosphorothioate oligodeoxynucleotides.
H. Liang (1996)
Protection against vaginal SIV transmission with microencapsulated vaccine.
P. Marx (1993)
The mucosal immune system: from fundamental concepts to vaccine development.
J. Mcghee (1992)
Haemoglobin polymorphism in the Rhesus macaque.
R. Basch (1972)
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
M. Roman (1997)
Detection of Human Cytokine‐Secreting Cells in Distinct Anatomical Compartments
C. Czerkinsky (1991)
Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
W. S. Gallichan (1996)
5 – Use of Escherichia coli Heat-Labile Enterotoxin as an Oral Adjuvant
B. L. Dickinson (1996)
Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins.
P. Giannasca (1997)
The role of nasopharyngeal lymphoid tissue.
C. Kuper (1992)
 Immunoglobulin A (IgA)
J. Mestecky (1985)
Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus
K. Yap (1978)
Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes
J. Tian (1996)
Gene therapy: adenovirus vectors.
K. Kozarsky (1993)
Microencapsulated human parainfluenza virus induces a protective immune response.
R. Ray (1993)
Immunology of the tonsils.
M. Perry (1998)
IL-12 is an effective adjuvant for induction of mucosal immunity.
P. Boyaka (1999)
Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity
M. Giuliani (1998)
Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
I. Belyakov (1999)
Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
M. Marinaro (1999)
ISCOMS--a novel strategy for mucosal immunization?
A. Mowat (1991)
Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization.
S. Czinn (1993)
Iscoms with different quillaja saponin components differ in their immunomodulating activities.
M. Johansson (1999)
Vaccinia: virus, vector, vaccine.
A. Piccini (1988)
CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus.
Z. Moldoveanu (1998)
Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.
B. Spangler (1992)
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.
A. Di Tommaso (1996)
Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes.
C. Partidos (1996)
Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function
R. Daynes (1990)
Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.
T. Wild (1992)
Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues.
M. Mcdermott (1979)
The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane.
S. Gizurarson (1991)
Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
L. Ågren (1999)
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA.
G. Smith (1983)
Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.
J. Mestecky (1987)
Human circulating specific antibody‐forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers
M. Quiding-Järbrink (1995)
CpG-rich islands and the function of DNA methylation
A. Bird (1986)
Mucosal immunity to vaccines: current concepts for vaccine development and immune response analysis.
J. Mcghee (1992)
Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi
S. Langermann (1994)
Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector.
G. Fennelly (1999)
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.
G. Douce (1997)
Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts.
L. Klavinskis (1999)
Antigen sampling across epithelial barriers and induction of mucosal immune responses.
M. Neutra (1996)
Adenovirus-based expression vectors and recombinant vaccines.
F. Graham (1992)
IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens.
H. Staats (1999)
Immunoglobulin A monoclonal antibodies protect against Sendai virus.
M. Mazanec (1987)
Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells.
J. L. Munoz (1991)
CpG motifs in bacterial DNA trigger direct B-cell activation
Arthur M. Krieg (1995)
Early Murine Cytomegalovirus (MCMV) Infection Induces Liver Natural Killer (NK) Cell Inflammation and Protection Through Macrophage Inflammatory Protein 1α (MIP-1α)–dependent Pathways
T. P. Salazar-Mather (1998)
Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres.
Y. Men (1996)
In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific
A. Lukacher (1984)
Th1 and Th2 cells.
C. Dong (2001)
New use of BCG for recombinant vaccines
C. Stover (1991)
Delivery of DNA vaccines by attenuated intracellular bacteria.
G. Dietrich (1999)
4 – Cholera Toxin as a Mucosal Adjuvant
C. Elson (1996)
Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant.
M. Yamamoto (1999)
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
T. Mosmann (1989)
Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides.
C. Partidos (1999)
This paper is referenced by
Anatomy of the Nasal Cavity in the Chinchilla
J. Jurcisek (2003)
Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination.
C. Partidos (2002)
Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization.
Q. Liu (2014)
Intranasal immunization with a non-adjuvanted adhesive protein descended from Pasteurella pneumotropica and its preventive efficacy against opportunistic infection in mice.
H. Sasaki (2013)
Evaluation of CpG-ODN-adjuvanted polyanhydride-based intranasal influenza nanovaccine in pigs.
S. Dhakal (2019)
Mucoadhesive Nanocarriers for Nasal Delivery of Vaccines
R. Sonawane (2016)
Liposome in situ gelling system: Novel carrier based vaccine adjuvant for intranasal delivery of recombinant protein vaccine
Shailja Tiwari (2009)
NALT (nasal cavity-associated lymphoid tissue) in the rabbit.
C. Casteleyn (2010)
Intranasal Administration of an Inactivated Yersinia pestis Vaccine with Interleukin-12 Generates Protective Immunity against Pneumonic Plague #
D. Kumar (2011)
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model.
Q. Liu (2016)
NK Cells Influence Both Innate and Adaptive Immune Responses after Mucosal Immunization with Antigen and Mucosal Adjuvant
L. Hall (2010)
Noninvasive immunization strategies to target dendritic cells and protect against experimental otitis media due to nontypeable Haemophilus influenzae
L. Novotny (2011)
Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with β2-adrenergic agonist
S. Kim (2009)
Development of alternative micro and nanoparticulate polymeric systems for mucosal delivery of Streptococcus equi antigens
H. Florindo (2008)
Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
Kapil Khatri (2008)
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
Intranasal administration of plasmid DNA‐coated nanoparticles results in enhanced immune responses
Z. Cui (2002)
Immunization onto bare skin with heat‐labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge
A. Beignon (2001)
Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination
Robert J. Garmise (2008)
Preparation and Efficacy of a Live Newcastle Disease Virus Vaccine Encapsulated in Chitosan Nanoparticles
K. Zhao (2012)
Generates Protective Immunity against Pneumonic Plague
Devender Kumar (2011)
The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice.
Omar Farnós (2006)
PREPARATION AND IN-VITRO EVALUATION OF SODIUM ALGINATE MICROSPHERES CONTAINING DIPHTHERIA TOXOID AS NEW VACCINE DELIVERY
A. Mokaram (2008)
Cationic Polylactic Acid-Based Nanoparticles Improve BSA-FITC Transport Across M Cells and Engulfment by Porcine Alveolar Macrophages
Puwich Chaikhumwang (2020)
Advances in effective vaccine development against hepatitis B: focus on mucosal vaccine delivery strategies.
Rishi Paliwal (2010)
Development of a nanogel-based nasal vaccine as a novel antigen delivery system
Rika Nakahashi-Ouchida (2017)
Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug
Sabrina Trows (2016)
IMMUNITY IN THE RESPIRATORY TRACT : THE ROLE OF IgA IN PROTECTION AGAINST INTRACELLULAR
A. Rodríguez (2005)
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Deborah Pushparajah (2021)
This information is current as Adjuvant Immunization with Antigen and Mucosal Immune Responses after Mucosal NK Cells Influence Both Innate and Adaptive
Lindsay J Hall (2010)
Preparation and evaluation of chitosan nanoparticles containing Diphtheria toxoid as new carriers for nasal vaccine delivery in mice
A. Mokarram (2006)See more